AMANDA LANCELEVE: Open Payments
NPI 1053037424 · HAVERHILL, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$464 in 23 payments from 8 companies in 2025. Trend: 2023 $327 · 2024 $778 · 2025 $464
Food & beverage: $464
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 11 | $157 |
| Teva Pharmaceuticals USA, Inc. | 3 | $86 |
| E.R. Squibb & Sons, L.L.C. | 2 | $71 |
| Lundbeck LLC | 3 | $65 |
| ABBVIE INC. | 1 | $24 |
| Indivior Inc. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
Products named: INGREZZA, REXULTI, COBENFY, UZEDY, AUSTEDO XR, VRAYLAR, SUBLOCADE, TRINTELLIX.
Industry payments across MA — which companies pay providers there.
